Literature DB >> 1929005

Utility of femorofemoral bypass. Comparison of results with indications for operation.

S B Self1, J D Richardson, T W Klamer, H W Kaebnick, G E Lambert, R A Mitchell.   

Abstract

Sixty-eight patients underwent femorofemoral bypass (FFB) at the University of Louisville Affiliated Hospitals over a 9-year period from 1980 to 1989. There were patients with acute ischemia requiring emergency operation, those with chronic ischemia following failed aortic reconstruction, good-risk patients with chronic ischemia who had FFB as the procedure of choice, and poor-risk patients who were unsuitable for other procedures. Patients operated on for acute ischemia had a significant number of infectious complications, with five of eight graft failures in this group due to infection. Primary patency rates were similar in all groups, with a 5-year primary patency of 42 per cent. Overall operative mortality was 4.4 per cent. Satisfactory limb salvage rates (75%) suggest that FFB is an acceptable option for providing inflow in patients with acute ischemia or for patients with a failed previous vascular prosthesis. FFB provides adequate inflow in poor-risk patients not suitable for aortic reconstruction, but patency rates do not warrant its use as a procedure of choice in good-risk patients.

Entities:  

Mesh:

Year:  1991        PMID: 1929005

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  2 in total

1.  Comparison of Direct and Less Invasive Techniques for the Treatment of Severe Aorto-Iliac Occlusive Disease.

Authors:  Kimberly C Zamor; Andrew W Hoel; Irene B Helenowski; Adam W Beck; Joseph R Schneider; Karen J Ho
Journal:  Ann Vasc Surg       Date:  2017-07-21       Impact factor: 1.466

2.  The impact of adjunctive iliac stenting on femoral-femoral bypass in contemporary practice.

Authors:  Chetan P Huded; Philip P Goodney; Richard J Powell; Brian W Nolan; Eva M Rzucidlo; Samuel T Simone; Daniel B Walsh; David H Stone
Journal:  J Vasc Surg       Date:  2012-01-05       Impact factor: 4.268

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.